Smith+Nephew Launching REDAPT Revision Hip in China

By Julie A. Vetalice

Smith+Nephew Launching REDAPT Revision Hip in China

Smith+Nephew gained approval from the National Medical Products Administration in China to introduce its REDAPT System for revision total hip arthroplasty in the region.

The REDAPT Revision Hip System is designed to address fixation in various bone types and achieve joint stability, predictable stem position and surgical efficiency.

REDAPT is designed to help lower the revision rate of total hip replacement by reducing the frequency of implant movement, which contributes to early failure.

REDAPT will be available in China later this year. The 3D-printed system launched in the U.S. in 2016.

Product Labels: Hip Replacement

Tags: Product Launch, Regulatory